NCT00130520View on ClinicalTrials.gov

Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

January 31, 2010

Study Completion Date

May 31, 2010

Conditions

Ovarian Neoplasms

Interventions

DRUG

bevacizumab

10mg/kg every two weeks IV-bevacizumab

DRUG

erlotinib

150mg daily by mouth-erlotinib

Trial Locations (1)

85724

University of Arizona Cancer Center, Tucson

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

University of Arizona

OTHER